Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hepapon DS is a hepatoprotective medication marketed by Makshi Healthcare, primarily indicated for the management of various liver disorders including fatty liver, alcoholic liver disease, and chronic hepatitis. It functions as a liver tonic to support hepatic detoxification and regeneration. The formulation typically combines silymarin, a flavonolignan complex derived from milk thistle (*Silybum marianum*), with L-ornithine L-aspartate (LOLA). Silymarin provides antioxidant and anti-inflammatory effects while stabilizing hepatocyte membranes and stimulating DNA-directed RNA polymerase I to enhance protein synthesis and tissue repair. L-ornithine L-aspartate acts as a substrate for the urea cycle and glutamine synthetase, effectively reducing elevated blood ammonia levels associated with hepatic dysfunction. This dual-action approach helps in detoxifying the liver and improving overall metabolic function in the context of hepatic insufficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hepapon DS.